Annals of Clinical Biochemistry > Volume 45, Number 6 > Pp. 560-566

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: acb.2008.008033v1 45/6/560    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stronge, R L Articles by Ardill, J E S Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original Articles

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

R L Stronge¹, G B Turner², B T Johnston³, D R McCance³, A McGinty⁴, C C Patterson⁵ and J E S Ardill³

¹ St George's Hospital Medical School, University of London; ² Altnagelvin Hospital, Londonderry; ³ Neuroendocrine Tumour Group, Royal Victoria Hospital; ⁴ School of Medicine; ⁵ Medical Statistics, Queen's University, Belfast, UK

Corresponding author: Professor Joy Ardill. Email: joyardill{at}belfasttrust.hscni.net

Aim: To assess the value of pancreastatin as a predictive factor for identifying patients with neuroendocrine tumours (NETs) who respond poorly to somatostatin analogues.

Methods: A retrospective study of patients with NETs. Patient records from the Northern Ireland Neuroendocrine Tumour Register were interrogated. Those who had pancreastatin concentrations measured on two or more occasions, before and during somatostatin analogue therapy (within the set time-limits) were selected. Data relating to diagnosis, surgery, somatostatin analogue therapy and survival outcome were noted. Data were subjected to univariate and multivariate analysis using Cox proportional hazard model.

Results: Fifty-nine patients with gastroenteropancreatic NETs fulfilled the inclusion criteria. Factors associated with a poor survival outcome on univariate analysis were primary tumour site (P = 0.006) and rapid rise in pancreastatin during somatostatin analogue treatment (P < 0.001). In multivariate analysis, highly significant clinical prognostic indicators were: tumour location (P < 0.001), pre-treatment pancreastatin (P < 0.001) and pancreastatin change (P < 0.001).

Conclusions: This study endorses the finding that pancreastatin is a useful prognostic indicator of neuroendocrine disease. On commencement of treatment, one-third of the subjects showed an immediate negative pancreastatin response to somatostatin analogues, which was associated with poor survival. This is the first study to document such an association. These findings have significant therapeutic consequences. In the presence of a rapidly rising pancreastatin alternative, treatment modalities should be sought.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?